H. Lundbeck ASHLUBF 78 EV-to-FCF is 10.41 as of Jul. 04, 2026, which is 7% above its 10-year median of 9.71. GuruFocus rates HLUBF with a GF Score™ of 78/100 and a GF Value™ of $5.65 (Fairly Valued). The stock has 3 warning signs investors should review. Among 562 Drug Manufacturers companies, H. Lundbeck AS ranks better than 76.69% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, H. Lundbeck AS's Enterprise Value is $7,838 Mil.
H. Lundbeck AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $753 Mil. Therefore, H. Lundbeck AS's EV-to-FCF for today is 10.41.
The historical rank and industry rank for H. Lundbeck AS's EV-to-FCF or its related term are showing as below:
HLUBF'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.81 Med: 9.71 Max: 28.52
Current: 10.26
During the past 13 years, the highest EV-to-FCF of H. Lundbeck AS was 28.52. The lowest was 5.81. And the median was 9.71.
HLUBF's EV-to-FCF is ranked better than 76.69% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs HLUBF: 10.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
H. Lundbeck AS (OTCPK:HLUBF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
H. Lundbeck AS's PE Ratio (TTM) for today is calculated as:
H. Lundbeck AS's share price for today is $5.50.
H. Lundbeck AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
H. Lundbeck AS EV-to-FCF Related Terms
H. Lundbeck AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's EV-to-FCF falls into.
H. Lundbeck AS's current Enterprise Value is $7,838 Mil.
H. Lundbeck AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $753 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H. Lundbeck AS (HLUBF) has a EV-to-FCF of 10.41 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on H. Lundbeck AS and its competitors. This is near median its historical median of 9.71. Over the past decade, H. Lundbeck AS's EV-to-FCF has ranged from 5.81 to 28.52. According to the industry distribution chart, H. Lundbeck AS ranks #131 out of 562 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is H. Lundbeck AS's EV-to-FCF too high?
H. Lundbeck AS's current EV-to-FCF of 10.41 is near median its 10-year median of 9.71. Over the past 10 years, this metric has ranged from a low of 5.81 to a high of 28.52. The Drug Manufacturers industry median EV-to-FCF is 20.53. H. Lundbeck AS's value of 10.41 is 49.3% below this industry median. Based on the distribution chart, H. Lundbeck AS ranks #131 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, H. Lundbeck AS has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #131 out of 562 companies for EV-to-FCF. This places H. Lundbeck AS in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.53. H. Lundbeck AS's value of 10.41 is 49.3% below this benchmark. Historically, H. Lundbeck AS's own EV-to-FCF has ranged from 5.81 to 28.52 over the past decade. While the company's 10-year median is 9.71 vs. the industry median of 20.53, H. Lundbeck AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current EV-to-FCF of 10.41 is 49.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current EV-to-FCF is 10.41, which is near median its own 10-year median of 9.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (HLUBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.65, compared to a current price of $5.50 — trading 2.7% below its estimated fair value. The current EV-to-FCF is 10.41, which is near median its 10-year median of 9.71 and 49.3% below the Drug Manufacturers industry median of 20.53. H. Lundbeck AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For H. Lundbeck AS (HLUBF), the current EV-to-FCF is 10.41 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (HLUBF) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of $5.50 is trading 2.7% below its estimated GF Value™ of $5.65.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for HLUBF:
EV-to-FCF: 10.41 (near median its 10-year median of 9.71)
GF Value™: $5.65 vs. price of $5.50 (2.7% below fair value)
Industry Position: 49.3% below the Drug Manufacturers median (#131 of 562)
No single metric tells the full story. See the HLUBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
78GF Score
Get the complete analysis for HLUBF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLUBF has been successfully added to your 
